• Vaccine Name: v2RVFH
• Target Pathogen: rinderpest virus
• Vaccine Ontology ID: VO_0004813
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Cattle
• RPVgp5 F gene engineering:
  • Type: Recombinant vector construction
  • Description: The vaccine v2RVFH is a recombinant vector vaccine that expresses two proteins including the F protein from the rinderpest virus (Verardi et al., 2002).
  • Detailed Gene Information: Click Here.
• RPVgp6 H gene engineering:
  • Type: Recombinant protein preparation
  • Description: The vaccine v2RVFH is a recombinant vector vaccine that expresses the H protein from a rinderpest virus (Verardi et al., 2002).
  • Detailed Gene Information: Click Here.
• Preparation: The v2RVFH vaccine was prepared by using a recombinant vaccinia virus vaccine to expresses both the fusion (F) and hemagglutinin (H) genes of rinderpest virus (RPV) under strong synthetic vaccinia virus promoters (Verardi et al., 2002).
• Immunization Route: Intramuscular injection (i.m.)

Cattle Response

• Host Strain: Zebu cattle
• Vaccination Protocol: Groups of Zebu cattle (Bos indicus, 2 years old on average) vaccinated intramuscularly (1 ml) with various doses of v2RVFH at the side of the neck. Control groups were also included (Verardi et al., 2002).
• Immune Response: Intramuscular vaccination of cattle with 10^8 PFU of v2RVFH provided long-term sterilizing immunity against rinderpest (Verardi et al., 2002).
• Side Effects: The vaccine is highly safe. Animals vaccinated with v2RVFH did not develop pock lesions and did not transmit the recombinant vaccinia virus to contact animals (Verardi et al., 2002).
• Challenge Protocol: Animals were challenged subcutaneously (1 ml) at the side of the neck with 10^3 to 10^4 TCID50 of the pathogenic Kabete ‘O’ RPV; as little as 1 TCID50 of the virus administered subcutaneously induces clinical rinderpest with 100% mortality in U.S. cattle. Nasal and ocular swabs were taken at 2, 3, 4, and 7 days postchallenge from a group of NVI animals challenged at 4 weeks postvaccination. In addition, prescapular and mesenteric lymph nodes as well as lung, spleen, tonsil, kidney, and heart tissue samples were taken from animals that died following RPV challenge. RPV isolation was attempted from the collected swabs and necropsy samples in primary calf cells (kidney and testis) and Vero cells (Verardi et al., 2002).
• Efficacy: Cattle vaccinated intramuscularly with as little as 10^3 PFU of v2RVFH and challenged 1 month later with a lethal dose of RPV were completely protected from clinical disease; the 50% protective dose was determined to be 102 PFU. Animals vaccinated with v2RVFH did not develop pock lesions and did not transmit the recombinant vaccinia virus to contact animals (Verardi et al., 2002).